STAT42%
FTC settles lawsuit with CVS Caremark over charges it manipulated insulin prices, impeded access 81%
By Ed Silverman61%
7/14/2026, 8:55:49 PM
BS Summary: This article contains 9 faulty reasoning types, including Confirmation Bias, Framing Effect, and Appeal to Emotion, with Negativity Bias as the most egregious example at 55.4% saturation with 97 hits. Analysis detected 490 faulty-reasoning hits from 175 analyzed words, generating a BS Score of 73% and a BS Rank of 81% (4,023 of 21,171 articles). This article is worse (more manipulative) than 81.00% of the article peer group.
The Federal Trade Commission settled a lawsuit against CVS Caremark, one of the largest pharmacy benefit managers in the U.S., over allegations that the company artificially inflated the price of insulin and impeded access to the lifesaving diabetes treatment.
As part of the deal, which the agency maintained will save Americans up to $8.5 billion in out-of-pocket costs over 10 years, CVS Caremark, which is owned by CVS Health, must make several changes to its dealings with employers, health plans, and pharmacies.
The FTC also estimated the deal will unlock up to $4.5 billion in further savings for patients through pharmacy counter rebates.
In its complaint, the FTC alleged that CVS Caremark — as well as Cigna’s Express Scripts and UnitedHealth’s Optum Rx — created a “perverse” system of rebates that favored insulin, which was then sold at higher list prices in order to “line their pockets” at the expense of patients who were forced to pay more for the medication.
Speakers
1speaker33%attributed speech117writer words
Voice mapSelect a segment to jump to its words
Selected voice
100%flagged-word coverageFederal Trade Commission
58 attributed words100% of attributed speech88% writer coverage
Attribution is sentence-level. Pattern percentages are calculated only from words assigned to that voice.
Loading…
Loading…
Loading…
Loading…
Analysis
Hover over highlighted words in the article to view the associated bias or fallacy analysis.